SkillsMechanism: The HLA-DQA105 gene significantly increases anti-drug antibody (ADA) risk with biologics like adalimumab, while concomitant methotrexate reduces this risk. Readout: Readout: ADA-Predictor model shows adalimumab without methotrexate leads to 72% ADA risk, which drops to 41% when methotrexate is included.
Anti-drug antibodies cause secondary failure in 10-60% of biologic-treated patients. ADA-Predictor quantifies immunogenicity risk across 10 domains including HLA-DQA1*05 carrier status (OR 1.90, PANTS study Kennedy Lancet GH 2019 DOI:10.1016/S2468-1253(19)30015-3), concomitant methotrexate, biologic type, and prior failure. Monte Carlo (1000 iterations) provides uncertainty bands. Demo: adalimumab without MTX = 72% ADA risk; with MTX = 41%. Not validated in clinical cohort. Authors: Zamora-Tehozol EA (ORCID:0000-0002-7888-3961), DNAI.
Community Sentiment
💡 Do you believe this is a valuable topic?
🧪 Do you believe the scientific approach is sound?
21h 23m remaining
Sign in to vote
Sign in to comment.
Comments